Table 1.

Polygenic risk score (PRS) of ulcerative colitis (UC) and Crohn’s disease (CD) as a predictor of time to development of all-grade and severe immune checkpoint inhibitor-mediated colitis (IMC) in the entire GeRI cohort, using Cox proportional hazards models and stratified analysis assessing the association between PRS_UC and all-grade/severe IMC by type of therapy and lung cancer histology

PRSa	All-grade IMC			Severe IMC
	HR per SD	95% CI	p	HR per SD	95% CI	p
PRSUC	1.34	1.02–1.76	0.04	1.62	1.12–2.35	0.01
PRSCD	0.97	0.72–1.32	0.87	0.99	0.66–1.46	0.94
Stratified analysis (Restricted to PRSUC)
Therapyb	All-grade IMC			Severe IMC
Anti-PD1/Anti-PD-L1 monotherapy	1.33	0.99–1.78	0.06	1.51	1.01–2.27	0.04
Anti-PD1/Anti-PD-L1 + Anti-CTLA4	1.64	0.67–4.03	0.28	4.31	1.08–17.24	0.03
Histologyc	All-grade IMC			Severe IMC
Adenocarcinoma	1.43	1.06–1.93	0.02	2.12	1.37–3.26	6×10−04
Squamous cell carcinoma	0.79	0.16–3.78	0.76	0.79	0.16–3.78	0.76

All p-values are two-sided.

Statistically significant results are highlighted in bold.

PRS polygenic risk score, IMC immune checkpoint inhibitor-mediated colitis, HR hazard ratio, SD standard deviation, CI confidence interval, UC ulcerative colitis, CD Crohn’s disease.

^aModels are adjusted for age at diagnosis, sex, histology, type of therapy, recruiting site, and 5 principal components.

^bModels are adjusted for age at diagnosis, sex, histology, recruiting site, and 5 principal components.

^cModels are adjusted for age at diagnosis, sex, type of therapy, recruiting site, and 5 principal components.